Regencell Bioscience Shareholder Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy RGC?
Source: PRnewswire
- Shareholder Alert: The Gross Law Firm has issued a notice to shareholders who purchased Regencell (NASDAQ:RGC) shares between October 28, 2024, and October 31, 2025, encouraging them to contact the firm for potential lead plaintiff appointment, highlighting the company's legal vulnerabilities.
- Market Manipulation Risks: The allegations claim that during the class period, Regencell issued materially false and misleading statements, failing to disclose its vulnerability to market manipulation, which exposed investors to significant financial risks and harmed the company's reputation.
- Legal Consequences: The heightened risk of regulatory and governmental scrutiny could lead to substantial legal, monetary, and reputational harm for the company, exacerbating investor concerns about the stability of their investments.
- Participation Opportunity: Shareholders must register by June 23, 2026, to participate in the class action, and upon registration, they will receive updates through portfolio monitoring software, ensuring their rights are protected throughout the case lifecycle.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regencell Bioscience Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating serious legal risks for the company.
- False Statements Allegations: The complaint alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose its vulnerability to market manipulation, which exposed investors to significant financial risks.
- Increased Regulatory Risks: Due to the alleged false statements, Regencell faces heightened scrutiny from regulators and potential governmental enforcement actions, which could lead to substantial legal, financial, and reputational harm, impacting its future operations.
- Investor Rights Protection: Investors have until June 23, 2026, to request to be appointed as lead plaintiff, with the law firm promising to charge fees only on a contingency basis if successful, ensuring that investors' rights are protected in the legal proceedings.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and significant financial risks, thereby impacting the company's reputation and legal standing.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in this field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, encouraging them to choose qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Regencell Bioscience Holdings Class Action Reminder for Investors
- Class Action Reminder: Robbins LLP reminds all investors who purchased Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect investor rights and seek compensation.
- Allegations of Market Manipulation: The lawsuit alleges that Regencell was affected by market manipulation during the class period, leading to significant stock price volatility and exposing investors to substantial financial risks, while also subjecting the company to heightened regulatory scrutiny.
- Expected Legal Costs: Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to recent market volatility, indicating that the company expects to incur significant legal costs and may have to pay fines exceeding its insurance coverage.
- Stock Price Impact: Following this news, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting market uncertainty and a decline in investor confidence regarding the company's future prospects.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: A class action lawsuit against LKQ Corporation alleges that from February 27, 2023, to July 23, 2025, executives failed to disclose significant risks related to customer losses at FinishMaster, which could negatively impact the company's reputation and stock price as investors suffered losses.
- Regencell Bioscience Lawsuit: Regencell Bioscience Holdings Limited faces a class action lawsuit for the period from October 28, 2024, to October 31, 2025, where it is accused of failing to disclose market manipulation risks, exposing investors to financial risks and potential regulatory scrutiny, which could hinder future growth.
- Globant S.A. Lawsuit: Globant S.A. is involved in a class action lawsuit covering February 15, 2024, to August 14, 2025, for not disclosing decreasing demand in Latin America and wage freezes, misleading investors about the company's prospects, which may have long-term negative effects on its market performance.
- Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of their rights to participate in these class actions, emphasizing the potential impact on future legal strategies and corporate governance structures.
See More
Regencell Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 28, 2024, and October 31, 2025, with a deadline to contact the firm by June 23, 2026.
- Market Manipulation Risks: The complaint alleges that Regencell made false and misleading statements, resulting in significant stock volatility due to market manipulation, which exposed the company to regulatory scrutiny and reputational damage, thereby undermining investor confidence.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover losses, as the Schall Law Firm specializes in securities class actions and offers free consultations to help affected shareholders understand their rights and take action.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who choose not to act will remain absent class members and may lose their opportunity to claim damages.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Transparent Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, minimizing financial burdens for participants.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this legal domain.
- Case Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to significant financial risks and potential regulatory scrutiny, which could adversely affect the company's reputation and financial health.
See More
Regencell Bioscience Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating serious legal risks for the company.
- False Statements Allegations: The complaint alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose its vulnerability to market manipulation, which exposed investors to significant financial risks.
- Increased Regulatory Risks: Due to the alleged false statements, Regencell faces heightened scrutiny from regulators and potential governmental enforcement actions, which could lead to substantial legal, financial, and reputational harm, impacting its future operations.
- Investor Rights Protection: Investors have until June 23, 2026, to request to be appointed as lead plaintiff, with the law firm promising to charge fees only on a contingency basis if successful, ensuring that investors' rights are protected in the legal proceedings.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and significant financial risks, thereby impacting the company's reputation and legal standing.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in this field.
- Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, encouraging them to choose qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Regencell Bioscience Holdings Class Action Reminder for Investors
- Class Action Reminder: Robbins LLP reminds all investors who purchased Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect investor rights and seek compensation.
- Allegations of Market Manipulation: The lawsuit alleges that Regencell was affected by market manipulation during the class period, leading to significant stock price volatility and exposing investors to substantial financial risks, while also subjecting the company to heightened regulatory scrutiny.
- Expected Legal Costs: Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to recent market volatility, indicating that the company expects to incur significant legal costs and may have to pay fines exceeding its insurance coverage.
- Stock Price Impact: Following this news, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting market uncertainty and a decline in investor confidence regarding the company's future prospects.
See More
Multiple Companies Face Class Action Lawsuits
- LKQ Corporation Lawsuit: A class action lawsuit against LKQ Corporation alleges that from February 27, 2023, to July 23, 2025, executives failed to disclose significant risks related to customer losses at FinishMaster, which could negatively impact the company's reputation and stock price as investors suffered losses.
- Regencell Bioscience Lawsuit: Regencell Bioscience Holdings Limited faces a class action lawsuit for the period from October 28, 2024, to October 31, 2025, where it is accused of failing to disclose market manipulation risks, exposing investors to financial risks and potential regulatory scrutiny, which could hinder future growth.
- Globant S.A. Lawsuit: Globant S.A. is involved in a class action lawsuit covering February 15, 2024, to August 14, 2025, for not disclosing decreasing demand in Latin America and wage freezes, misleading investors about the company's prospects, which may have long-term negative effects on its market performance.
- Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of their rights to participate in these class actions, emphasizing the potential impact on future legal strategies and corporate governance structures.
See More
Regencell Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 28, 2024, and October 31, 2025, with a deadline to contact the firm by June 23, 2026.
- Market Manipulation Risks: The complaint alleges that Regencell made false and misleading statements, resulting in significant stock volatility due to market manipulation, which exposed the company to regulatory scrutiny and reputational damage, thereby undermining investor confidence.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover losses, as the Schall Law Firm specializes in securities class actions and offers free consultations to help affected shareholders understand their rights and take action.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who choose not to act will remain absent class members and may lose their opportunity to claim damages.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- Transparent Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, minimizing financial burdens for participants.
- Firm's Track Record: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this legal domain.
- Case Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to significant financial risks and potential regulatory scrutiny, which could adversely affect the company's reputation and financial health.
See More
